Key patent application by J & J for TB drug rejected
The company had filed a patent for Fumarate salt of bedaquiline in 2008 to extend its patent till the end of 2027. It was under review by the patent office. The strategy is called patent evergreening used by companies to keep the prices high as it would keep the affordably priced generic versions of the drug out of the market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 23, 2023 Category: Pharmaceuticals Source Type: news
Eight-Week Bedaquiline-Linezolid Noninferior for TB
TUESDAY, Feb. 28, 2023 -- A strategy of eight weeks of bedaquiline-linezolid is noninferior to a standard regimen for tuberculosis, according to a study published online Feb. 20 in the New England Journal of Medicine to coincide with the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 28, 2023 Category: Pharmaceuticals Source Type: news
Study Affirms Shorter Regimens for Drug-Resistant Tuberculosis Study Affirms Shorter Regimens for Drug-Resistant Tuberculosis
Two short-course bedaquiline-containing regimens are promising treatment options for multidrug-resistant tuberculosis.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 17, 2022 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
Anti-diabetes drugs and patented antivirals to get cheaper, NLEM notified
For the first time, patented drugs like anti-TB bedaquiline and delamanid, anti-HIV Dolutegravir and anti-hepatitis C daclatasvir are also a part of the NLEM. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 12, 2022 Category: Pharmaceuticals Source Type: news
Bedaquiline - Pretomanid - Linezolid Regimens Compared for XDR TB
Overall risk - benefit ratio seems to favor patients receiving linezolid at dose of 600 mg for 26 weeks (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 16, 2022 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Pharmacy, Pulmonology, Journal, Source Type: news
Bedaquiline-Pretomanid-Linezolid Regimens Compared for XDR TB
FRIDAY, Sept. 16, 2022 -- For patients with extensively drug-resistant (XDR) tuberculosis, the overall risk-benefit ratio seems to favor patients receiving the bedaquiline-pretomanid-linezolid regimen with linezolid at a dose of 600 mg for 26 weeks,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 16, 2022 Category: Pharmaceuticals Source Type: news
Getting patented meds on NLEM list an uphill battle says committee member
As many as 34 new drugs were added and 26 dropped from an updated list of essential medicines.For the first time patented drugs like anti-TB drugs Bedaquiline and Delamanid, anti-HIV Dolutegravir and anti-hepatitis C Daclatasvir are also a part of the NLEM 2022 and their prices are set to get cheaper. Union health minister Mansukh Mandaviya released the revised NLEM on Tuesday. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 15, 2022 Category: Pharmaceuticals Source Type: news
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
August 17, 2022 – The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development. The collaboration will evaluate whether the novel regimens, which combine registered products and new chemical entities (NCEs), can effectively treat all forms of active pulmonary TB using substantially shorter treatment durations than existing drug regimens, with the goal of identifying a regimen suitable for phase 3 develo...
Source: Johnson and Johnson - August 17, 2022 Category: Pharmaceuticals Source Type: news
Nail in the Coffin for Injectable Therapy in Drug-Resistant TB?
(MedPage Today) -- Oral treatment containing bedaquiline was associated with better outcomes for patients with drug-resistant tuberculosis (TB) compared with an injectable treatment regimen, a retrospective cohort study showed.
In adjusted analyses... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - May 4, 2022 Category: Infectious Diseases Source Type: news
Africa: Lifesaving TB Medicines Still Out of Reach for Children in High-Burden Countries
[MSF] The World Health Organization (WHO) recently released new rapid guidance recommending that children of all ages with drug-resistant tuberculosis (DR-TB) have access to all-oral treatment using the drugs bedaquiline and/or delamanid. (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - September 3, 2021 Category: Infectious Diseases Source Type: news
Government slashes prices of about 39 commonly-used drugs
The drugs brought under price control include teneligliptin-an anti diabetes drug, popular anti TB drugs like Bedaquiline and Delamanid, Ivermectin used in Covid treatment, Rotavirus vaccine, among others. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 3, 2021 Category: Pharmaceuticals Source Type: news
BPaL regimen can cut time for treatment of drug-resistant TB
BPaL is a six-month, alloral, three-drug regimen that is used to treat people with highly drug-resistant forms of TB. It consists of the TB Alliance developed antibiotic pretomanid, along with two other antibiotics: bedaquiline and linezolid. (Source: The Economic Times)
Source: The Economic Times - July 22, 2021 Category: Consumer Health News Source Type: news
Africa: Active TB Drug Safety Monitoring and Management (ADSM) Global Database - Outcome of the Assessment and Future of Data Reporting
[WHO] A global database set up by WHO's Global Tuberculosis Programme in collaboration with the Special Programme for Research and Training in Tropical Diseases (TDR) has been collating data on Active TB Drug Safety Monitoring and Management (aDSM) since 2016, to monitor the safety of patients who receive MDR-TB treatment with new medicines (e.g. bedaquiline, delamanid), repurposed medicines (e.g. linezolid, clofazimine) or new regimens, which don't have a well-established safety profile. The aDSM framework has (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - July 12, 2021 Category: Infectious Diseases Source Type: news
Bedaquiline for Disseminated NTM Infection in HIV Patients Bedaquiline for Disseminated NTM Infection in HIV Patients
Could this novel antimycobacterial agent provide a safe and effective treatment option for NTM infections in HIV patients?Emerging Infectious Diseases (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 6, 2021 Category: Infectious Diseases Tags: Infectious Diseases Journal Article Source Type: news
Trinity scientists find that binding iron improves the effect of anti-TB drug Bedaquiline
(Trinity College Dublin) For some time, scientists have known that depriving infections of iron can limit bacterial burden and help improve patient outcomes. Now scientists at Trinity College and St James's Hospital have recently applied such a trick (of binding iron to support the immune system) to the treatment of TB, along with a new TB antimicrobial called Bedaquiline. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 22, 2021 Category: Infectious Diseases Source Type: news
